A

AlloVir
D

ALVR

0.42400
USD
0.00
(0.52%)
Market Open
Volume
2,412
EPS
0
Div Yield
-
P/E
-0
Market Cap
49,000,404
OverviewSignalsIdeasNews
Related Instruments
    AAPL
    AAPL
    0.090
    (0.04%)
    254.530 USD
    AMZN
    AMZN
    1.120
    (0.50%)
    226.290 USD
    GOOGL
    GOOGL
    2.040
    (1.07%)
    193.580 USD
    MSFT
    MSFT
    -3.23
    (-0.74%)
    434.43 USD
    NVDA
    NVDA
    3.220
    (2.39%)
    138.090 USD
    S
    SNAP
    -0.270
    (-2.37%)
    11.130 USD
    TSLA
    TSLA
    9.19
    (2.18%)
    431.00 USD
    ZM
    ZM
    -0.430
    (-0.50%)
    85.230 USD
    More
News

Title: AlloVir

Sector: Healthcare
Industry: Biotechnology
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.